Invesco SandP MidCap 400 GARP ETF (GRPM)

Looking at the macroeconomic backdrop for mid-caps, the Federal Reserve holding policy rates at 4.25% to 4.50% alongside a softening manufacturing PMI below 50 creates real near-term earnings noise. However, GRPM's valuation at a P/E of 15.20x gives us a solid discount compared to the Small Blend category average of 17.26x. That valuation cushion is exactly what we need while navigating ongoing tariff uncertainties in the industrial and economically sensitive sectors.

Examining the short interest data as of mid-July 2026, short positions dropped by 43.71% down to just 703 shares, representing a negligible 0.02% of the public float. With a days-to-cover ratio of 0.1 based on average daily volume of 16,881 shares, short sellers have virtually zero conviction against this fund. That matches our view that downward pressure is strictly macro-driven rather than stock-specific bearishness.

On our desk, reviewing the risk metrics for GRPM reveals a classic high-beta, aggressive setup. The fund carries a 10-year beta of 1.14 and a risk score of 82 out of 100, which labels it as Very Aggressive. Even though its 5-year Sharpe of 0.36 beats the category median of 0.29, its 3-year downside capture of 129 shows it still absorbs notable pain during rising-volatility sessions. We have to treat this strictly as a full-market-cycle equity holding rather than a defensive parking spot.

When analyzing execution costs and liquidity protocols for factor ETFs, I noticed GRPM maintains a reasonable expense ratio of 0.35%, but the wide 0.21% bid-ask spread adds explicit friction. With a 75% annual portfolio turnover, frequent short-term trading is clearly inefficient here. Instead, our institutional mandate treats it as a long-term allocation where patience on entry and exit pricing is vital to avoid slippage.

From an institutional accumulation perspective, Q2 2026 regulatory filings show 96 hedge funds and large institutions holding $287 million in GRPM. Although 10 funds closed positions, 34 increased their holdings, keeping aggregate participation stable. The underlying fundamental thesis is supported by a solid 1-year gain of 28.65% and a 10-year annualized return of 10.87%, confirming that patient capital remains committed despite the 5-year CAGR lagging at 6.77%.